Ikarian Capital’s Traws Pharma TRAW Stock Holding History

Ikarian Capital’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Sell	478,142 -200,000	-29%	-$276K	0.04%	127
2026 Q1	$1.24M	Hold	678,142	–	–	0.1%	108
2025 Q4	$766K	Buy	678,142 +649,649	+2,280%	+$1.44M	0.06%	132
2025 Q3	$52.7K	Hold	28,493	–	–	0.01%	165
2025 Q2	$42.2K	Hold	28,493	–	–	0.01%	129
2025 Q1	$65.5K	Sell	28,493 -70,000	-71%	-$364K	0.01%	154
2024 Q4	$875K	Buy	+98,493	New	+$548K	0.12%	112
2022 Q2	–	Sell	-759	Closed	-$35K	–	209
2022 Q1	$35K	Buy	759 +156	+26%	+$7.23K	﹤0.01%	188
2021 Q4	$37K	Hold	603	–	–	0.01%	176
2021 Q3	$57K	Sell	603 -326	-35%	-$42K	﹤0.01%	208
2021 Q2	$161K	Sell	929 -2,125	-70%	-$481K	0.01%	208
2021 Q1	$1.14M	Buy	+3,054	New	+$1.15M	0.04%	233

Other funds holding TRAW

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Ikarian Capital's TRAW Position: Q2 2026 in Review

Ikarian Capital reduced its Traws Pharma (TRAW) stake by 29% in Q2 2026, selling an estimated $276K and leaving 478,142 shares worth $403K. The position accounts for 0.04% of the portfolio, ranked #127.

Ikarian Capital first reported a position in TRAW in Q1 2021 and has held it in 12 quarters since. The position peaked at $1.24M in Q1 2026. 34 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

Ikarian Capital held 478,142 shares of Traws Pharma worth $403K as of Q2 2026.
Ikarian Capital sold 200,000 Traws Pharma shares in Q2 2026, an estimated $276K.
Traws Pharma made up 0.04% of Ikarian Capital's portfolio in Q2 2026, its #127 holding.
Ikarian Capital first reported a position in Traws Pharma in Q1 2021 and has held it in 12 quarters since.
Ikarian Capital's Traws Pharma position peaked at $1.24M in Q1 2026.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.